Monoclonal Gammopathy
11
2
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
Pre-malignant States to Hematologic Malignancies in Firefighters
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
Rifaximin in Patients With Monoclonal Gammopathy
Multi-center Screening for Serum M Protein
Screening for Monoclonal Gammopathy in Individuals Undergoing Physical Examinations Using iMS-LC Assay Technology.
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
Frequency and Characteristics of Pruritus in Patients With Monoclonal Gammopathy
A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early
Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy
Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis